TK Rao, Ph.D.
Founder and Chairman of the Board
Dr. Rao, founder and Chairman of the Board of the Directors at Integrated Laboratory Systems, Inc. (ILS). He graduated with a Ph.D. from Florida State University. Before founding ILS, he worked as a Staff Biologist at Oak Ridge National Laboratory in Tennessee and Senior Research Scientist at Northrop Services, Inc. in North Carolina. Dr. Rao served on various professional organizations such as The Environmental Mutagen Society, Genetic Toxicology and Environmental Mutagen Society, Southeastern Cancer Research Association and The National Contract Management Association. He has edited one reference book and has published over 150 technical publications and presentations.
President and Board Member
Todd Grosshandler is President of ILS, and serves as one of its board members. Mr. Grosshandler brings to this position a well-established background as a life science executive with more than 25 years of experience in the CRO sector, serving both federal and commercial clients.
An entrepreneur at heart, Mr. Grosshandler co-founded Enthalpy Analytical in 1993 and grew his successful environmental and bioanalytical CRO for more than 18 years, consistently delivering double digit growth and EBITDA. He sold Enthalpy to LabCorp in 2010 and successfully led the integration efforts once acquired.
Serving on the senior management team for LabCorp’s bioanalytical division, known as Tandem Labs, Mr. Grosshandler assumed operational and sales responsibilities and helped to deliver unprecedented sales growth and profitability for Tandem.
He was selected to serve on the due diligence and core integration team when LabCorp acquired Covance in 2015. Following the integration, Mr. Grosshandler assumed broader responsibilities for the combined organization and served as an Executive Director for Business Development at Covance. In this role, he was responsible for supporting the commercial strategy and sales team deployment/management for Covance’s full range of preclinical services.
Mr. Grosshandler has a strong track record of leading, implementing, and executing operational improvements, strategic sales, and multi-media marketing campaigns, and consistently delivering strong financial performance. He is a graduate of NCSU’s College of Physical & Mathematical Sciences with a degree in Chemistry (magna cum laude).
Les Recio, Ph.D. DABT
VP, Research and Development
Dr. Recio is the Chief Scientist at ILS. Dr. Recio’s responsibilities include defining the scope of work, providing oversight and organization for all studies, and training of staff in genetic and molecular toxicology methods. He provides supervision of all genetic toxicology and genomic based projects through prioritization, coordination, and scheduling of all activities. Dr. Recio guides the development of new capabilities for novel approaches for use in the assessment of genotoxicity. He interacts with ILS staff to develop new programs and provide new avenues for research projects. Dr. Recio was appointed to the Editorial Board of Toxicological Sciences and was elected to the North Carolina Society of Toxicology Board of Councilors in 2006. Dr. Recio received both his M.S. and Ph.D. in Toxicology from the University of Kentucky. After completion of a postdoctoral fellowship in 1989, Dr. Recio became a Senior Research Fellow in the Cellular and Molecular Toxicology Department of the Chemical Industry Institute of Toxicology (CIIT). While at CIIT (1989 to 2002), Dr. Recio’s research group published more than 70 manuscripts in peer-reviewed literature in the area of molecular biology, genetic toxicology, and carcinogenesis.
David Allen, Ph.D.
VP, Science and Strategy
As the VP of Science and Strategy at ILS, Dr. Allen provides scientific leadership, management, and direction to ILS’ programs and core services. He works closely with all scientific staff to support the planning and execution of ILS growth plans, and leads staff planning and employee development. Dr. Allen has over 15 years of experience in regulatory toxicology, test method validation, and in vitro biology. At ILS, Dr. Allen has spent over 8 years providing contract support and leadership for the National Toxicology Program’s Center for the Evaluation of Alternative Toxicological Methods (NICEATM). Prior to joining ILS, he was a toxicologist for the Food and Drug Administration, Center for Drug Evaluation and Research, where he was responsible for evaluating toxicological and pharmacological data for investigational new drug applications. Dr. Allen received his B.S. in Zoology from North Carolina State University, his M.S. in Biological Sciences from the University of North Carolina at Wilmington, and his Ph.D. in Cell Biology also from North Carolina State University.
Brad Blackard, MSPH
VP, Business Management
Mr. Blackard has over 25 years of experience in the environmental health science industry and over 15 years of experience managing federal contracts. After serving as a Program Manager for six years, Director of Operations for two years, and the Chief Operating Officer for five years, he is now the Vice-President of Business Management for ILS. His role includes managing the daily and long-term business operations of the company including Finance, Contracts, Human Resources, Information Technology, Quality Assurance, Health and Safety, and Facility Administration. He works with the President to assure the aggressive and successful growth of the company. Mr. Blackard holds a B.S. in Zoology from North Carolina State University, and a MSPH in Environmental Sciences and Engineering, Environmental Management and Policy from the University of North Carolina at Chapel Hill.